Cencora, Inc. COR
At closeNov 3, 2026, 7:39 PM EST
After hours · Nov 3, 7:39 PM ET
- YTD
- +0.81%
- 1 year
- -0.13%
- Market cap
- 64.98B
- Revenue (ttm)
- 332.77B
- Profit margin
- 0.79%
- EPS (ttm)
- 13.47
- Shares out
- 190.83M
- P/E ratio
- 25.28
- Forward P/E
- 17.23
- Dividend
- 2.40 (0.71%)
- Ex-dividend date
- Aug 13, 2026
- YTD return
- +0.81%
- 1-year return
- -0.13%
- Volume
- 1.65M
- Avg volume
- 1.31M
- Open
- 335.90
- Previous close
- 337.84
- Day's range
- 334.31 – 342.09
- 52-week range
- 244.82 – 377.54
- Beta
- 0.57
- Analysts
- Buy
- Price target
- 371.67 (+9.2%)
- Earnings date
- Nov 4, 2026
5D +17.24 (+5.33%)
Key statistics
- Enterprise value
- 76.30B
- PEG ratio
- 0.71
- Price / sales
- 0.20
- Price / book
- 21.30
- Dividend yield
- 0.71%
- Payout ratio
- 17.45%
- Revenue growth
- 5.10%
- Free cash flow
- 2.04B
- Total cash
- 2.82B
- Total debt
- 14.46B
- Return on equity
- 96.87%
- Short % of float
- 2.35%
- 50-day average
- 323.77
- 200-day average
- 317.00
Analyst view
Consensus: buy
- Target (low)
- 330.00
- Target (mean)
- 371.67
- Target (high)
- 400.00
- Strong buy3
- Buy7
- Hold4
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 4.57.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 4.58 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 4.35 | 4.48 | +0.13 | +2.99% |
| May 6, 2026 | Mar 31, 2026 | 4.82 | 4.75 | -0.07 | -1.45% |
| Feb 4, 2026 | Dec 31, 2025 | 4.05 | 4.08 | +0.03 | +0.74% |
| Nov 5, 2025 | Sep 30, 2025 | 3.79 | 3.84 | +0.05 | +1.32% |
| Aug 6, 2025 | Jun 30, 2025 | 3.85 | 4.00 | +0.15 | +3.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 22, 2026 | Baird | main | Outperform | Outperform |
| Oct 20, 2026 | Argus Research | main | Buy | Buy |
| Oct 16, 2026 | UBS | main | Buy | Buy |
| Oct 7, 2026 | Leerink Partners | main | Outperform | Outperform |
| Sep 8, 2026 | RBC Capital | reit | Sector Perform | Sector Perform |
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Country
- United States
- Website
- cencora.com
News
ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test 
Why Cencora (COR) is a Top Growth Stock for the Long-Term 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Lumentum Holdings Inc. (Nasdaq – LITE), Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC) 
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November 
Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $377 
Cencora Gears Up to Report Q4 Results: How to Play the Stock? 
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics 
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth 
Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ)
Your note
Sign in to keep a note on COR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BATTAGLIA SILVANA | Officer | Stock Award(Grant) | Jun 29, 2026 | 23,624 |
| CAMPBELL ELIZABETH S | Officer | Sale | Aug 23, 2026 | 19,455 |
| CLEARY JAMES F. JR. | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 10, 2026 | 160,357 |
| COLLIS STEVEN HOWARD | Officer and Director | Sale | Sep 15, 2025 | 305,913 |
| DURCAN DERMOT MARK | Director | Purchase | Jun 17, 2026 | 31,767 |
| GREENBERG LON R | Director | Sale | Sep 15, 2026 | 17,128 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.54% | 18,213,783 | 6.20B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.49% | 12,378,943 | 4.22B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.04% | 9,611,756 | 3.27B | Jun 29, 2026 |
| State Street Corporation | 4.86% | 9,273,983 | 3.16B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 3.88% | 7,410,910 | 2.52B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 3.74% | 7,132,687 | 2.43B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.07% | 5,867,758 | 2.00B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.64% | 5,041,886 | 1.72B | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.33% | 4,437,584 | 1.51B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.10% | 4,005,017 | 1.36B | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.59% | 3,033,825 | 1.03B | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,543,056 | 866.09M | Sep 29, 2026 |